Chloroquine-d5

Chloroquine-d5 is deuterium labeled Chloroquine (HY-17589A) . Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM) [1][2][3][4].

Product Specifications

CAS Number

[1854126-41-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; HIV; Isotope-Labeled Compounds; Parasite; SARS-CoV; Toll-like Receptor (TLR)

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Autophagy; Immunology/Inflammation; Others

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection; Inflammation/Immunology

Purity

99.90

Solubility

10 mM in DMSO|DMSO : 50mg/mL (ultrasonic)

Smiles

CC(NC1=CC=NC2=CC(Cl)=CC=C12)CCCN(CC)C([2H])([2H])C([2H])([2H])[2H]

Molecular Formula

C18H21D5ClN3

Molecular Weight

324.90

Precautions

H302, H315, H319, H335

References & Citations

[1]Said A, et al. Chloroquine promotes IL-17 production by CD4+ T cells via p38-dependent IL-23 release by monocyte-derived Langerhans-like cells. J Immunol. 2014 Dec 15;193 (12) :6135-43.|[2]Tuomela J, et al. Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer. Oncol Lett. 2013 Dec;6 (6) :1665-1672.|[3]Mohamed FE, et al. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2014 Jul 2. doi: 10.1111/liv.12626.|[4]Colson P, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55 (4) :105932.|[5]Savarino A, et al. The anti-HIV-1 activity of chloroquine. J Clin Virol. 2001;20 (3) :131-135.